联合检测CEA、CA199和CA242在胰腺癌诊断中的应用价值

目的探讨用蛋白芯片法检测CEA、CA199和CA242在胰腺癌诊断中应用价值。方法用蛋白芯片法测定38例胰腺癌患者、65例非胰腺恶性肿瘤患者、37例良性疾病患者和20例健康人群血清CEA、CA199和CA242含量。结果CEA、CA199和CA242对胰腺癌有诊断价值，其中敏感性、特异性、阳性预测值、阴性预测值分别为60．3％、61．4％、36．3％和80．3％；81．3％、72．5％、52．6％和89．3％；79．0％、84．2％、64．5％和90．3％；联合检测可提高检测的特异性和阳性预测值。结论联合检测CEA、CA199和CA242有利于胰腺癌临床诊断。     

巨噬细胞抑制因子-1在胃癌中的作用

巨噬细胞抑制因子-1(macrophage inhibitory gytokine-1, MIC-1)是人转化生长因子β(transforming growth factor-β,TGF-β)超家族中的一个重要分支成员, 在胃癌等多种肿瘤有过度表达. 大量研究表明, MIC-1在胃癌早期通过诱导凋亡和抑制过度增生表现抑癌生物学活性, 但近期有报道, 在胃癌进展期因为内环境等的变化, MIC-1具有促癌作用, 其机制包括: 抑制连环蛋白cateninδ1基因的表达;上调uPA系统增强胃癌肿瘤细胞侵袭性; 诱导ErbB2受体酪氨酸激酶在人体胃癌细胞等过度表达. 胃癌组织过度表达MIC-1和uPA提示预后不良, 故可以作为判断胃癌预后的指标.     

巨噬细胞游走抑制因子在冠心病诊断及治疗中的价值

<正>巨噬细胞游走抑制因子(macrophage migration.inhibitory factor,MIF)是1966年发现的一种高度保守的与炎症性疾病密切相关的因子。炎症在冠状动脉粥样硬化发生发展中发挥着重要的作用,研究发现MIF通过其促炎及促基质金属蛋白酶(matrix metalloproteinases,MMPs)表达的作用,参与了动脉粥样硬化的发生及发展过程.且可降低动脉粥样硬化斑块的稳定性,在急性冠状动脉综合征(acute coronary syndrome,ACS)的发病中发挥着重要的作用。本文将简述MIF在冠心病诊断与治疗中的潜在的临床应用价值。     

巨噬细胞移动抑制因子在胰腺癌组织中的表达及其与预后的关系

目的研究胰腺癌组织巨噬细胞移动抑制因子（MIF）的表达与肿瘤发生、发展、血管生成的意义及其对预后的影响。方法应用免疫组化方法检测31例胰腺癌组织、癌旁组织、14例正常胰腺组织中MIF表达水平,并进行微血管计数,并分析MIF表达与临床病理特点的关系及对胰腺癌预后的影响。结果胰腺癌组织MIF表达明显高于癌旁组织和正常胰腺组织（P〈0.01）,癌旁组织高于正常胰腺组织（P〈0.01）。MIF的表达与肿瘤分化程度及远处转移有关（P〈0.05）,MIF表达阳性胰腺癌组织和癌旁组织微血管密度高于MIF表达阴性癌组织及癌旁组织（P〈0.05）。MIF表达阳性患者生存期与MIF表达阴性患者无统计学差异。结论 MIF对胰腺癌的发生、发展及肿瘤血管生成起重要作用,直接或间接影响着肿瘤的生长、侵袭和转移。MIF的表达与患者预后无关。     

1b型慢性丙型肝炎患者血清巨噬细胞抑制因子-1水平升高临床价值分析

目的 探讨血清巨噬细胞抑制因子-1(MIC-1)水平对基因1b型慢性丙型肝炎(CHC)的影响。方法 2016年1月至2019年3月收治的1b型CHC患者84例。以聚乙二醇干扰素+利巴韦林联合治疗,采用单因素、多因素分析比较不同病毒学应答结果1b型CHC患者资料。结果 84例1b型CHC患者中病毒学应答61例,未应答组23例。应答组年龄为45(37,55)岁,高于未应答组的36(33,44)岁(P<0.05)。应答组ALT、AST、PⅢNP、C-Ⅳ及MIC-1为40(15,82)U/L、37(18,94)U/L、27.0(10.1,114.6)ng/mL、28.4(11.5,108.4)ng/mL及298.8(145.2,746.8)pg/mL,低于未应答组的56(26,122)U/L、49(22,120)U/L、33.7(11.3,160.6)ng/mL、36.7(14.1,170.1)ng/mL及646.3(156.7,1540.3)pg/mL(P<0.05)。84例1b型CHC患者治疗前MIC-1为714.8(171.0,1582.1)pg/mL,高于治疗后的365.0...     

血清巨噬细胞抑制细胞因子-1在胰腺癌诊断中的价值

胰腺癌是一种临床症状隐匿、发展迅速、预后差的消化系统恶性肿瘤,根治性手术是改善预后的惟一手段.     

巨噬细胞移动抑制因子在乙型肝炎病毒感染相关性肝病中的表达

巨噬细胞移动抑制因子(MIF)存在于多种器官的正常组织中,并参与多种疾病的病理形成过程,近年研究发现其在胃癌、肝癌及食管癌等肿瘤组织中呈高表达。本研究的目的在于检测MIF在CHB、重症肝炎、肝炎肝硬化和HCC中的表达差异,探讨MIF参与HBV感染相关性病变的可能机制。一、资料与方法1.对象:病理肝组织标本取自1996年10月至2005年     

老年肝硬化患者血清恶性肿瘤生长因子和巨噬细胞抑制因子-1的水平

目的探讨老年肝硬化患者血清恶性肿瘤生长因子(TSGF)和巨噬细胞抑制因子(MIC)-1水平及其在肝硬化严重程度中的意义。方法选择老年乙型肝炎肝硬化患者120例作为肝硬化组(B组),根据肝功能Child-Pugh分级分为肝功能A级(48例)、肝功能B级(46例)、肝功能C级(26例)三个亚组;根据是否合并腹水分为肝硬化合并腹水(54例)和肝硬化不合并腹水(66例)两个亚组。选择同期120例健康体检者为对照组(A组)。采用Child-Pugh分级法进行肝功能分级。采用速率法测定血清TSGF水平。采用酶联免疫吸附试验(ELISA)测定血清MIC-1水平。结果 B组血清TSGF和MIC-1水平明显高于A组(P0.05)。与肝功能A级比较,肝功能B级和肝功能C级患者血清TSGF和MIC-1水平明显升高(均P0.05);与肝功能B级比较,肝功能C级患者血清TSGF和MIC-1水平明显升高(均P0.05)。有腹水组患者血清TSGF和MIC-1水平明显高于无腹水组(P0.05)。结论老年乙型肝炎肝硬化患者血清TSGF和MIC-1水平升高,升高水平与肝硬化的肝功能分级和是否存在腹水关系密切。     

巨噬细胞游走抑制因子在急性胰腺炎发病机制中的作用

炎症介质和免疫因素在急性胰腺炎(acute pancreatltis，AP)发病机制中的作用已得到肯定，同时资料表明巨噬细胞游走抑制因子(macrophage migration inhibitory factor，MIF)在许多炎症和免疫性疾病中起关键作用。MIF在AP发病机制中的作用及MIF抗体在急性胰腺炎中应用的研究亦取得很大进展。     

血清巨噬细胞移动抑制因子检测在儿童哮喘防治中临床意义

目的 探讨血清巨噬细胞移动抑制因子在儿童哮喘防治中的意义.方法 选取随访的缓解期哮喘患儿87例,健康对照组30例,检测巨噬细胞移动抑制因子（MIF）、嗜酸性粒细胞阳离子蛋白（ECP）及粉尘螨特异性IgE（DF-sIgE）.分析比较哮喘患儿与健康儿童血清MIF、ECP、DF-sIgE及嗜酸性粒细胞计数检测结果.结果 缓解期哮喘患儿血清MIF、ECP及嗜酸性粒细胞计数均较正常对照组升高,差异具有统计学意义.缓解期重度持续哮喘患儿血清MIF较轻度间歇、轻度持续及中度持续患儿更高,差异具有统计学意义.粉尘螨致敏的缓解期哮喘患儿血清DF-sIgE与MIF及ECP相关性研究显示,三者互相之间均有正相关关系.结论 血清MIF与变应性哮喘患者的炎症指标有密切关系,检测血清MIF对缓解期哮喘患儿的病情判断具有重要的参考价值.     

直肠癌中MIC-1, VEGF和P53表达的临床意义

目的: 探讨直肠癌中巨噬细胞抑制因子-1(MIC-1), 血管内皮生长因子(VEGF), P53基因蛋白表达与病理特征的相关性.方法:用免疫组化法检测73例直肠癌中MIC-1, VEGF和P53的表达, 并与临床病理因素进行相关性分析.结果: MIC-1, VEGF, P53表达均与直肠癌临床分期显著相关(χ2MIC-1 = 37.534, χ2VEGF = 54.451, χ2P53 = 16.834;P<0.01);三者联合阳性表达率与临床分期呈显著线性相关(r = 0.918, P = 0.000). MIC-1表达与VEGF, P53表达呈正相关(r = 0.808, r = 0.369, P<0.01).结论:MIC-1, VEGF, P53在直肠癌发生、发展中呈协同和相互调节作用, 联合检测他们的阳性表达有助于直肠癌侵润转移的判断.     

2型糖尿病患者血清巨噬细胞抑制因子-1与颈动脉粥样斑块相关性的观察

目的 探讨T2DM患者血清巨噬细胞抑制因子-1（MIC-1）与颈动脉粥样斑块的相关性.方法 根据多普勒超声结果,将113例T2DM患者分为合并颈动脉粥样斑块组（A,n=55）与单纯T2DM组（B,n=58）,另选正常对照组（C,n=57）.ELISA测定研究对象血清MIC-1水平. 结果 A、B组血清MIC-1水平高于C组（P＜0.01）,A组高于B组（P＜0.01）.相关分析显示,血清MIC-1水平与FPG、HbA1 c、SBP、DBP、TG、肿瘤坏死因子α（TNF-α）呈正相关（r=0.183、0.287、0.173、0.194、0.270、0.287,P＜0.05）,与HDL-C呈负相关（r=-0.410,P＜0.01）.多元线性逐步回归分析表明,HbA1 c、TG、HDL-C是血清MIC-1水平的独立影响因素（β=0.204、0.176、0.296,P＜0.05）. 结论 T2DM患者血清MIC-1水平升高,T2DM合并颈动脉粥样斑块患者血清MIC-1水平较单纯T2DM患者进一步升高.HbA1c、TG、HDL-C是MIC-1的独立相关因素.     

肠癌患者血清巨噬细胞抑制因子-1、神经肽Y的表达与食欲减退的相关性

[目的]探讨肠癌患者血清巨噬细胞抑制因子-1(MIC-1)、神经肽Y(NPY)的表达及其与患者食欲减退的相关性.[方法]采用ELISA法测定34例晚期肠癌患者3个月前后血清MIC-1、NPY的表达,并进行食欲评分和体质指数计算.[结果]研究前34例患者MIC1、NPY水平分别为(947.55±82.83)、(118.59±8.55) pg/ml;随访3个月后有6例患者死亡,余28例患者MIC-1水平升高为(1195.09±122.32) pg/ml,NPY水平下降至(99.20±7.33)pg/ml;前、后比较均差异有统计学意义(P＜0.01).3个月后食欲评分及体质指数均较研究前下降;食欲评分及体质指数与血清MIC-1呈显著负相关,与NPY呈显著正相关(均P＜0.01).[结论]晚期肠癌患者血清MIC-1表达升高而NPY表达下降,两者与食欲评分及体质指数的下降密切相关,是导致晚期肠癌患者食欲减退和体质量下降的原因之一.     

A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer

BackgroundK-ras codon 12 mutation is one of the earliest genetic changes in the development of pancreatic cancer (PC) and accurate detection of K-ras mutations is gaining increasing attention in the field of molecular diagnosis.MethodsOriginal research articles which evaluated the diagnostic accuracy of K-ras mutation detection in PC were selected. Data were presented as forest plots and summary receiver operating characteristic curve analysis was used to summarize the overall test performance.ResultsWe assessed 16 studies from 15 published articles. The pooled sensitivity and specificity were 59% (95%CI: 54%–64%) and 87% (95%CI: 84%–89%), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 4.13 (95%CI: 2.73–6.25) and 0.42 (95%CI: 0.32–0.56), respectively, and the pooled diagnostic odds ratio was 13.66 (95% CI: 7.25–25.74).ConclusionsOur results indicate that the analysis of K-ras mutations in pancreatic juice has a considerable diagnostic value in PC. Further studies with rigorous design, large sample size, and multi-regional co-operation are needed.     

Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo

Background and Study AimsThis study was designed to compare the antitumor effects of anti-human MUC1 monoclonal antibody with those of anti-human CA199 monoclonal antibody coupled with drug-loaded polybutylcyanoacrylate nanoparticles on human pancreatic cancer cell lines and pancreatic cancer-bearing model animals and to screen more efficient targeting molecules.Patients and MethodsGemcitabine-loaded nanospheres were prepared by emulsion polymerization (GEM-PBCA-NP), and then, anti-MUC1 monoclonal antibody was coupled with GEM-PBCA-NP (MUC1-GEM-PBCA-NP), and anti-human CA199 monoclonal antibody was coupled with GEM-PBCA-NP (CA199-GEM-PBCA-NP), using the chemical crosslinking method. The cell-killing rates were detected using MTT assay. The changes in the tumor cell cycle and apoptosis after treatment were detected using flow cytometry. Then, the subcutaneous planting method was adopted to establish an animal model of pancreatic cancer: two nanometer microspheres were injected into the body of nude mice via the tail vein; the tumor suppression effect was detected after treatment; then, the groups were compared.ResultsIn vitro, the cell-killing rate of each experimental group was significantly different from that of the control group (P < 05). The MUC1-GEM-PBCA-NP group had a significantly higher cell-killing rate than the other groups (P < 05). The apoptosis rate of the MUC1-GEM-PBCA-NP treatment group was significantly higher than that of other groups (P < 05). In vivo, the tumor inhibition rate of the MUC1-GEM-PBCA-NP treatment group was 72.69% ± 4.29%, which was significantly higher than those of other groups (P < 0.05). The tumor inhibition rate of the CA199-GEM-PBCA-NP treatment group was 56.58% ± 5.11%, which was significantly higher than those of other control groups (P < 0.05). At the end of treatment, the average tumor mass of the MUC1-GEM-PBCA-NP treatment group was 433.55 ± 12.49 mg, which was significantly lower than those of other groups (P < 0.05).ConclusionCompared with CA199-GEM-PBCA-NP, MUC1-GEM-PBCA-NP is more effective in vitro and in vivo. MUC1 could be a target molecule in treating pancreatic cancer.     

Interleukin-8, a promising predictor for prognosis of pancreatic cancer

AIM: To investigate the value of interleukin-8 (IL-8), a pro-inflammatory chemokine, in predicting the prognosis of pancreatic cancer.METHODS: Expression of IL-8 and its receptor CXCR1 was assessed by immunohistochemistry in pancreatic cancer and chronic pancreatitis samples. Enzyme-linked immunosorbent assay was used to detect the serum IL-8 levels in pancreatic cancer patients. Human pancreatic cancer tissues were heterotopically transplanted to the immune-deficiency mice to evaluate the effect of serum IL-8 on the tumorigenesis of the cancer samples.RESULTS: IL-8 and CXCR1 proteins were both over-expressed in pancreatic adenocarcinoma samples (55.6% and 65.4%, respectively) compared with the matched para-cancer tissues (25.9% and 12.3%, P < 0.01), or chronic pancreatitis (0% and 25%, P < 0.05). Serum IL-8 levels in pancreatic cancer patients (271.1 ± 187.7 ng/mL) were higher than in other digestive system tumors, such as gastric cancer (41.77 ± 9.11 ng/mL, P = 0.025), colorectal carcinoma (78.72 ± 80.60 ng/mL, P = 0.032) and hepatocellular carcinoma (59.60 ± 19.80 ng/mL, P = 0.016). In vivo tumorigenesis analysis further proved that tumor tissues from patients with higher serum IL-8 levels grew faster than those with lower IL-8 levels.CONCLUSION: IL-8 can be a fine serum marker for predicting the prognosis pancreatic cancer.     

酶联免疫吸附试验检测大沙鼠心血冲洗液中鼠疫F1抗体的可行性分析

目的 分析酶联免疫吸附试验(ELISA)法检测大沙鼠心血冲洗液鼠疫F1抗体的可行性及其在鼠疫监测工作中的应用价值.方法 2007年,在准噶尔盆地大沙鼠鼠疫疫源地,采用弓形夹捕获大沙鼠.取大沙鼠血清、心血冲洗液和肝脾浸液,用ELISA法检测鼠疫F1抗体的阳性检出率和阳性滴度.数据处理用SPSS 17.0.结果 大沙鼠鼠疫F1抗体的阳性检出率与平均阳性滴度,血清分别为12.35%(20/162)和2535;心血冲洗液分别为10.49%(17/162)和23.75,肝脾浸液分别为6.79%(11/162)和2240.血清鼠疫F1抗体的阳性检出率与心血冲洗液比较,差异无统计学意义(χ2=1.333,P＞0.05),与肝脾浸液比较,差异有统计学意义(χ2=7.111,P＜0.0l);心血冲洗液与肝脾浸液比较,差异有统计学意义(χ2=6.250,P＜0.05).鼠疫F1抗体平均滴度,血清与心血冲洗液和肝脾浸液比较,差异有统计学意义(t值分别为2.290,3.612,P＜0.05或＜0.01).鼠疫F1抗体阳性符合率,血清与心血冲洗液为85.0%(17/20),与肝脾浸液为55.0%(11/20);心血冲洗液与肝脾浸液为64.7%(11/17).结论 ELISA法能检测到鼠心血冲洗液中鼠疫F1抗体,在鼠疫监测中,利用鼠心血冲洗液测定鼠疫F1抗体具有可行性.

Abstract：

Objective To analyse the feasibility of detecting F1 antibody to Yersinia pestis in flushing fluid of heart blood of Rhombomys opimus with enzyme linked immunosorbent assay(ELISA) method and its application value in surveillance of the disease. Methods Serum, flushing fluid of heart blood and infusion fluid of liver and spleen of Rhombomys opimus, which were caught by capture in the plague focus of Zunger basin in 2007, were taken to carry out detection for F1 antibodies to Yersinia pestis with ELISA method. The data were processed with SPSS 17.0. Results Positive rate and average titer of serum were 12.35%(11/162) and 25.35, of flushing fluid of heart blood were 10.49%(17/162) and 23.75 and of the infusion fluid of liver and spleen 6.79%(17/162) and 2240,respectively. No statistical difference was found in positive detection rate when it was compared between serum and flushing fluid of heart blood(χ2 = 1.333, P ＞ 0.05), but it was obviously different between serum and infusion fluid of liver and spleen(χ2 = 7.111, P ＜ 0.01 ) and between flushing fluid of heart blood and infusion fluid of liver and spleen(x2 = 6.250, P ＜ 0.05). There was a significant difference in average titer between serum, flushing fluid of heart blood and infusion fluid of liver and spleen(t = 2.290, 3.612, P ＜ 0.05 or ＜ 0.01 ). The plague F1 antibody positive coincidence rate of serum and flushing fluid of heart blood was 85.0%(17/20), of serum and infusion fluid of liver and spleen was 55.0% (11/20), and of flushing fluid of heart blood and infusion fluid of liver and spleen was 64.7%(11/17). Conclusions The ELISA method can detect Fl antibody in flushing fluid of heart blood,and the method is feasible in plague surveillance.     

巨噬细胞抑制因子-1及尿激酶型纤容酶原激活剂在胃癌组织中的表达及临床病理意义

目的:探讨巨噬细胞抑制因子-1(macrophage inhibitory cytokine-1,MIC-1)及尿激酶型纤容酶原激活剂(urokinase plasminogen activator,uPA)在胃癌组织中的蛋白表达及其临床意义.方法:收集郑州大学第一附属医院2009-01/2010-05胃癌存档蜡块55...